Apoptosis as a determinant of tumor sensitivity to topotecan in human ovarian tumors: Preclinical in vitro/in vivo studies

Claudia Caserini, Graziella Pratesi, Monica Tortoreto, Barbara Bedogné, Nives Carenini, Rosanna Supino, Paola Perego, Sabina C. Righetti, Franco Zunino

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Preclinical and clinical studies have documented the pharmacological interest in camptothecin derivatives in the treatment of resistant tumors. In particular, topotecan, a water-soluble derivative, exhibited promising activity in pretreated ovarian carcinoma. The present study investigated the pattern of tumor response in two human ovarian carcinoma xenografts and in their cisplatin-resistant sublines characterized by different mechanisms of drug resistance. In IGROV-1/Pt1 cells, cisplatin resistance has been ascribed to a reduced susceptibility to apoptosis as a consequence of p53 mutation and inactivation of its function. In the A2780 cisplatin-resistant subline, which retained the wild-type p53 gene status, the development of resistance has been possibly related to increased cell ability to repair drug-induced DNA damage. The in vivo results of the present study showed that topotecan could overcome the resistance in A2780/CP but not in IGROV-1/Pt1 tumor xenografts. The pattern of tumor response following in vivo topotecan treatment correlated. with drug ability to induce apoptosis but not with its in vitro antiproliferative activity. The antitumor efficacy of topotecan in the four tumors reflected a different cell response to drug-induced DNA damage, as suggested by different perturbations of cell cycle progression. Indeed, only in the subline refractory to topotecan in vivo, IGROV-1/Pt1, did we observe a persistent arrest of the cells in the S-phase, resulting in a cytostatic and not a cytotoxic effect, since a low level of apoptosis was induced by the drug. In conclusion, the current results support that determination of drug-induced apoptosis is a useful predictor of tumor response to topotecan in ovarian carcinomas and suggest that p53 gene status may be a critical determinant of cell response to topoisomerase inhibitors.

Original languageEnglish
Pages (from-to)955-961
Number of pages7
JournalClinical Cancer Research
Volume3
Issue number6
Publication statusPublished - Jun 1997

Fingerprint

Topotecan
Apoptosis
Cisplatin
Neoplasms
Pharmaceutical Preparations
p53 Genes
Carcinoma
Heterografts
DNA Damage
Topoisomerase Inhibitors
Camptothecin
Cytostatic Agents
S Phase
Drug Resistance
In Vitro Techniques
Cell Cycle
Pharmacology
Mutation
Water

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Caserini, C., Pratesi, G., Tortoreto, M., Bedogné, B., Carenini, N., Supino, R., ... Zunino, F. (1997). Apoptosis as a determinant of tumor sensitivity to topotecan in human ovarian tumors: Preclinical in vitro/in vivo studies. Clinical Cancer Research, 3(6), 955-961.

Apoptosis as a determinant of tumor sensitivity to topotecan in human ovarian tumors : Preclinical in vitro/in vivo studies. / Caserini, Claudia; Pratesi, Graziella; Tortoreto, Monica; Bedogné, Barbara; Carenini, Nives; Supino, Rosanna; Perego, Paola; Righetti, Sabina C.; Zunino, Franco.

In: Clinical Cancer Research, Vol. 3, No. 6, 06.1997, p. 955-961.

Research output: Contribution to journalArticle

Caserini, C, Pratesi, G, Tortoreto, M, Bedogné, B, Carenini, N, Supino, R, Perego, P, Righetti, SC & Zunino, F 1997, 'Apoptosis as a determinant of tumor sensitivity to topotecan in human ovarian tumors: Preclinical in vitro/in vivo studies', Clinical Cancer Research, vol. 3, no. 6, pp. 955-961.
Caserini C, Pratesi G, Tortoreto M, Bedogné B, Carenini N, Supino R et al. Apoptosis as a determinant of tumor sensitivity to topotecan in human ovarian tumors: Preclinical in vitro/in vivo studies. Clinical Cancer Research. 1997 Jun;3(6):955-961.
Caserini, Claudia ; Pratesi, Graziella ; Tortoreto, Monica ; Bedogné, Barbara ; Carenini, Nives ; Supino, Rosanna ; Perego, Paola ; Righetti, Sabina C. ; Zunino, Franco. / Apoptosis as a determinant of tumor sensitivity to topotecan in human ovarian tumors : Preclinical in vitro/in vivo studies. In: Clinical Cancer Research. 1997 ; Vol. 3, No. 6. pp. 955-961.
@article{e08142639beb4dceb61a3a8910bfa87f,
title = "Apoptosis as a determinant of tumor sensitivity to topotecan in human ovarian tumors: Preclinical in vitro/in vivo studies",
abstract = "Preclinical and clinical studies have documented the pharmacological interest in camptothecin derivatives in the treatment of resistant tumors. In particular, topotecan, a water-soluble derivative, exhibited promising activity in pretreated ovarian carcinoma. The present study investigated the pattern of tumor response in two human ovarian carcinoma xenografts and in their cisplatin-resistant sublines characterized by different mechanisms of drug resistance. In IGROV-1/Pt1 cells, cisplatin resistance has been ascribed to a reduced susceptibility to apoptosis as a consequence of p53 mutation and inactivation of its function. In the A2780 cisplatin-resistant subline, which retained the wild-type p53 gene status, the development of resistance has been possibly related to increased cell ability to repair drug-induced DNA damage. The in vivo results of the present study showed that topotecan could overcome the resistance in A2780/CP but not in IGROV-1/Pt1 tumor xenografts. The pattern of tumor response following in vivo topotecan treatment correlated. with drug ability to induce apoptosis but not with its in vitro antiproliferative activity. The antitumor efficacy of topotecan in the four tumors reflected a different cell response to drug-induced DNA damage, as suggested by different perturbations of cell cycle progression. Indeed, only in the subline refractory to topotecan in vivo, IGROV-1/Pt1, did we observe a persistent arrest of the cells in the S-phase, resulting in a cytostatic and not a cytotoxic effect, since a low level of apoptosis was induced by the drug. In conclusion, the current results support that determination of drug-induced apoptosis is a useful predictor of tumor response to topotecan in ovarian carcinomas and suggest that p53 gene status may be a critical determinant of cell response to topoisomerase inhibitors.",
author = "Claudia Caserini and Graziella Pratesi and Monica Tortoreto and Barbara Bedogn{\'e} and Nives Carenini and Rosanna Supino and Paola Perego and Righetti, {Sabina C.} and Franco Zunino",
year = "1997",
month = "6",
language = "English",
volume = "3",
pages = "955--961",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "6",

}

TY - JOUR

T1 - Apoptosis as a determinant of tumor sensitivity to topotecan in human ovarian tumors

T2 - Preclinical in vitro/in vivo studies

AU - Caserini, Claudia

AU - Pratesi, Graziella

AU - Tortoreto, Monica

AU - Bedogné, Barbara

AU - Carenini, Nives

AU - Supino, Rosanna

AU - Perego, Paola

AU - Righetti, Sabina C.

AU - Zunino, Franco

PY - 1997/6

Y1 - 1997/6

N2 - Preclinical and clinical studies have documented the pharmacological interest in camptothecin derivatives in the treatment of resistant tumors. In particular, topotecan, a water-soluble derivative, exhibited promising activity in pretreated ovarian carcinoma. The present study investigated the pattern of tumor response in two human ovarian carcinoma xenografts and in their cisplatin-resistant sublines characterized by different mechanisms of drug resistance. In IGROV-1/Pt1 cells, cisplatin resistance has been ascribed to a reduced susceptibility to apoptosis as a consequence of p53 mutation and inactivation of its function. In the A2780 cisplatin-resistant subline, which retained the wild-type p53 gene status, the development of resistance has been possibly related to increased cell ability to repair drug-induced DNA damage. The in vivo results of the present study showed that topotecan could overcome the resistance in A2780/CP but not in IGROV-1/Pt1 tumor xenografts. The pattern of tumor response following in vivo topotecan treatment correlated. with drug ability to induce apoptosis but not with its in vitro antiproliferative activity. The antitumor efficacy of topotecan in the four tumors reflected a different cell response to drug-induced DNA damage, as suggested by different perturbations of cell cycle progression. Indeed, only in the subline refractory to topotecan in vivo, IGROV-1/Pt1, did we observe a persistent arrest of the cells in the S-phase, resulting in a cytostatic and not a cytotoxic effect, since a low level of apoptosis was induced by the drug. In conclusion, the current results support that determination of drug-induced apoptosis is a useful predictor of tumor response to topotecan in ovarian carcinomas and suggest that p53 gene status may be a critical determinant of cell response to topoisomerase inhibitors.

AB - Preclinical and clinical studies have documented the pharmacological interest in camptothecin derivatives in the treatment of resistant tumors. In particular, topotecan, a water-soluble derivative, exhibited promising activity in pretreated ovarian carcinoma. The present study investigated the pattern of tumor response in two human ovarian carcinoma xenografts and in their cisplatin-resistant sublines characterized by different mechanisms of drug resistance. In IGROV-1/Pt1 cells, cisplatin resistance has been ascribed to a reduced susceptibility to apoptosis as a consequence of p53 mutation and inactivation of its function. In the A2780 cisplatin-resistant subline, which retained the wild-type p53 gene status, the development of resistance has been possibly related to increased cell ability to repair drug-induced DNA damage. The in vivo results of the present study showed that topotecan could overcome the resistance in A2780/CP but not in IGROV-1/Pt1 tumor xenografts. The pattern of tumor response following in vivo topotecan treatment correlated. with drug ability to induce apoptosis but not with its in vitro antiproliferative activity. The antitumor efficacy of topotecan in the four tumors reflected a different cell response to drug-induced DNA damage, as suggested by different perturbations of cell cycle progression. Indeed, only in the subline refractory to topotecan in vivo, IGROV-1/Pt1, did we observe a persistent arrest of the cells in the S-phase, resulting in a cytostatic and not a cytotoxic effect, since a low level of apoptosis was induced by the drug. In conclusion, the current results support that determination of drug-induced apoptosis is a useful predictor of tumor response to topotecan in ovarian carcinomas and suggest that p53 gene status may be a critical determinant of cell response to topoisomerase inhibitors.

UR - http://www.scopus.com/inward/record.url?scp=0030948772&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030948772&partnerID=8YFLogxK

M3 - Article

C2 - 9815771

AN - SCOPUS:0030948772

VL - 3

SP - 955

EP - 961

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 6

ER -